Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies

Chiara Cordiglieri, Fulvio Baggi, Pia Bernasconi, Dimos Kapetis, Elisa Faggiani, Alessandra Consonni, Francesca Andreetta, Rita Frangiamore, Paolo Confalonieri, Carlo Antozzi, Renato Mantegazza

Research output: Contribution to journalArticle

Abstract

Multiple Sclerosis (MS) is an inflammatory disease with neurodegenerative alterations, ultimately progressing to neurological handicap. Therapies are effective in counteracting inflammation but not neurodegeneration. Biomarkers predicting disease course or treatment response are lacking. We investigated whether altered gene and protein expression profiles were detectable in the peripheral blood of 78 relapsing remitting MS (RR-MS) patients treated by disease-modifying therapies. A discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100β. A longitudinal study on glatiramer acetate, Interferon-β, or Fingolimod treated RR-MS patients confirmed that 7 out of 8 genes were downregulated with reference to the different therapies, whereas S100β was always upregulated. Thus, we identified a peripheral gene signature associated with positive response in RR-MS which may also explain drug immunomodulatory effects. The usefulness of this signature as a biomarker needs confirmation on larger series of patients.

Original languageEnglish
Pages (from-to)133-146
Number of pages14
JournalClinical Immunology
Volume173
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Transcriptome
Multiple Sclerosis
Biomarkers
Genes
Relapsing-Remitting Multiple Sclerosis
Validation Studies
Therapeutics
Neurodegenerative Diseases
Interferons
Longitudinal Studies
Down-Regulation
Inflammation
Pharmaceutical Preparations
Proteins
Glatiramer Acetate

Keywords

  • Multiple sclerosis
  • Peripheral blood biomarkers
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. / Cordiglieri, Chiara; Baggi, Fulvio; Bernasconi, Pia; Kapetis, Dimos; Faggiani, Elisa; Consonni, Alessandra; Andreetta, Francesca; Frangiamore, Rita; Confalonieri, Paolo; Antozzi, Carlo; Mantegazza, Renato.

In: Clinical Immunology, Vol. 173, 01.12.2016, p. 133-146.

Research output: Contribution to journalArticle

Cordiglieri, C, Baggi, F, Bernasconi, P, Kapetis, D, Faggiani, E, Consonni, A, Andreetta, F, Frangiamore, R, Confalonieri, P, Antozzi, C & Mantegazza, R 2016, 'Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies', Clinical Immunology, vol. 173, pp. 133-146. https://doi.org/10.1016/j.clim.2016.10.002
Cordiglieri, Chiara ; Baggi, Fulvio ; Bernasconi, Pia ; Kapetis, Dimos ; Faggiani, Elisa ; Consonni, Alessandra ; Andreetta, Francesca ; Frangiamore, Rita ; Confalonieri, Paolo ; Antozzi, Carlo ; Mantegazza, Renato. / Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. In: Clinical Immunology. 2016 ; Vol. 173. pp. 133-146.
@article{335214380ad040779e4b91341cc75913,
title = "Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies",
abstract = "Multiple Sclerosis (MS) is an inflammatory disease with neurodegenerative alterations, ultimately progressing to neurological handicap. Therapies are effective in counteracting inflammation but not neurodegeneration. Biomarkers predicting disease course or treatment response are lacking. We investigated whether altered gene and protein expression profiles were detectable in the peripheral blood of 78 relapsing remitting MS (RR-MS) patients treated by disease-modifying therapies. A discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100β. A longitudinal study on glatiramer acetate, Interferon-β, or Fingolimod treated RR-MS patients confirmed that 7 out of 8 genes were downregulated with reference to the different therapies, whereas S100β was always upregulated. Thus, we identified a peripheral gene signature associated with positive response in RR-MS which may also explain drug immunomodulatory effects. The usefulness of this signature as a biomarker needs confirmation on larger series of patients.",
keywords = "Multiple sclerosis, Peripheral blood biomarkers, Therapy",
author = "Chiara Cordiglieri and Fulvio Baggi and Pia Bernasconi and Dimos Kapetis and Elisa Faggiani and Alessandra Consonni and Francesca Andreetta and Rita Frangiamore and Paolo Confalonieri and Carlo Antozzi and Renato Mantegazza",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.clim.2016.10.002",
language = "English",
volume = "173",
pages = "133--146",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies

AU - Cordiglieri, Chiara

AU - Baggi, Fulvio

AU - Bernasconi, Pia

AU - Kapetis, Dimos

AU - Faggiani, Elisa

AU - Consonni, Alessandra

AU - Andreetta, Francesca

AU - Frangiamore, Rita

AU - Confalonieri, Paolo

AU - Antozzi, Carlo

AU - Mantegazza, Renato

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Multiple Sclerosis (MS) is an inflammatory disease with neurodegenerative alterations, ultimately progressing to neurological handicap. Therapies are effective in counteracting inflammation but not neurodegeneration. Biomarkers predicting disease course or treatment response are lacking. We investigated whether altered gene and protein expression profiles were detectable in the peripheral blood of 78 relapsing remitting MS (RR-MS) patients treated by disease-modifying therapies. A discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100β. A longitudinal study on glatiramer acetate, Interferon-β, or Fingolimod treated RR-MS patients confirmed that 7 out of 8 genes were downregulated with reference to the different therapies, whereas S100β was always upregulated. Thus, we identified a peripheral gene signature associated with positive response in RR-MS which may also explain drug immunomodulatory effects. The usefulness of this signature as a biomarker needs confirmation on larger series of patients.

AB - Multiple Sclerosis (MS) is an inflammatory disease with neurodegenerative alterations, ultimately progressing to neurological handicap. Therapies are effective in counteracting inflammation but not neurodegeneration. Biomarkers predicting disease course or treatment response are lacking. We investigated whether altered gene and protein expression profiles were detectable in the peripheral blood of 78 relapsing remitting MS (RR-MS) patients treated by disease-modifying therapies. A discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100β. A longitudinal study on glatiramer acetate, Interferon-β, or Fingolimod treated RR-MS patients confirmed that 7 out of 8 genes were downregulated with reference to the different therapies, whereas S100β was always upregulated. Thus, we identified a peripheral gene signature associated with positive response in RR-MS which may also explain drug immunomodulatory effects. The usefulness of this signature as a biomarker needs confirmation on larger series of patients.

KW - Multiple sclerosis

KW - Peripheral blood biomarkers

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85002246078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002246078&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2016.10.002

DO - 10.1016/j.clim.2016.10.002

M3 - Article

AN - SCOPUS:85002246078

VL - 173

SP - 133

EP - 146

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -